imber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Timber Pharmaceuticals (NYSE American: TMBR) will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. The virtual presentation is scheduled for September 16th at 12:30 PM ET, featuring CEO John Koconis, who will provide a corporate overview and engage in one-on-one meetings with investors. Timber focuses on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis and localized scleroderma. For more details, visit timberpharma.com.
- None.
- None.
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET
WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference being held virtually from September 14-16, 2020. Timber’s presentation is scheduled for Wednesday, September 16th at 12:30 PM ET.
John Koconis, Chief Executive Officer of Timber, will be presenting a corporate overview to a live audience and will be available for virtual one-on-one meetings with investors throughout the conference.
The online presentation will be webcast live and can be accessed by following this link: https://wsw.com/webcast/hcw7/tmbr/1614541
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit www.timberpharma.com.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
Timber Pharmaceuticals, Inc. John Koconis Chief Executive Officer jkoconis@timberpharma.com Investor Relations: Stephanie Prince PCG Advisory (646) 762-4518 sprince@pcgadvisory.com
FAQ
What is the date of Timber Pharmaceuticals' presentation at the H.C. Wainwright conference?
Who is presenting for Timber Pharmaceuticals at the conference?
What is the focus of Timber Pharmaceuticals?
How can investors access the Timber Pharmaceuticals presentation?
What diseases does Timber Pharmaceuticals aim to treat?
